Medical Cannabis Patients in the UK Report Widespread Benefits in Landmark Releaf Survey

The latest nationwide survey from Releaf UK, one of the country’s licensed online medical cannabis clinics, has revealed that a strong majority of patients report meaningful improvements to their health and quality of life from prescribed cannabis-based treatments. The findings, gathered from more than 1,600 participants, arrive seven years after medical cannabis was legalized in Britain, marking a pivotal moment in assessing how the therapy is being used and perceived across the country.

According to the report, nearly every respondent—97 percent—said cannabis prescriptions improved their quality of life, with about two-thirds describing the change as “significant.” The data paints a striking picture of a treatment landscape that, while still maturing under strict regulation, appears to be delivering practical benefits to patients managing chronic pain, mental health conditions, and other enduring illnesses. Yet the results also illuminate persistent social stigma and policy friction that continue to shape patient experiences in the UK’s evolving cannabis sector.

From Legalization to Practice: A Slow Shift in Acceptance

Medical cannabis has been legal in the UK since November 2018 following a landmark government decision that enabled specialist doctors to prescribe cannabis-based products for medicinal use (CBPMs). Despite that authorization, access has remained tightly restricted. For several years, only a handful of National Health Service (NHS) prescriptions were issued. Most patients have had to turn to private clinics like Releaf UK to secure prescriptions and consistent medication supply.

Releaf’s results suggest a growing number of people are now turning to these private providers. The London-based clinic reports more than 100,000 registered patients since its founding in 2022. The study surveyed 1,669 of these patients—making it one of the largest datasets ever collected on prescribed medical cannabis in the UK. It offers valuable insight into demographics, treatment outcomes, and shifting attitudes toward a treatment once considered controversial.

Quantifying Patient Outcomes

The Releaf study identified a number of measures where cannabis therapy has had notable effects. Among respondents:

• 97 percent reported an improved quality of life, with 65 percent describing improvement as “significant.”
• 78 percent rated their cannabis-based treatment as “highly effective.”
• 88 percent reported no side effects, pointing to a generally favorable tolerability profile.
• 91 percent said they would recommend medical cannabis to others experiencing similar conditions.

These numbers represent a level of satisfaction rarely seen in initial post-legalization surveys. Experts interpret them as a sign that cannabis-based medicines, when properly supervised by qualified clinicians, are finding a stable place in chronic disease management strategies.

A pain medicine consultant commenting on the report described it as “encouraging evidence that legal, prescribed cannabis products are filling a care gap for patients who have failed to achieve relief through conventional therapies.” The consultant cautioned that while such patient-reported outcomes cannot replace randomized controlled trials, they remain a valuable complement to clinical data, offering a more nuanced understanding of how these medications function in real-world conditions.

What Conditions Are Being Treated?

The majority of survey participants reported managing multiple conditions, reflecting the complexity of typical cannabis therapy cases. Almost three-quarters (72 percent) said they were treating more than one issue. Chronic pain was the predominant primary condition, cited by 47.5 percent of respondents. Mental health conditions, including anxiety and depression, followed at 31 percent, while neurological disorders such as multiple sclerosis or epilepsy comprised 10 percent. Sleep-related disorders were the primary concern for about 6 percent.

Conditions like cancer-related symptoms, gastroenterological disorders, and women’s health issues represented smaller proportions—each below 3 percent. Those figures, while low, align with trends in current prescription data where most cannabis-based treatments target chronic pain and treatment-resistant psychological distress. Health analysts indicate the low uptake for cancer and gastrointestinal conditions reflects continued caution among prescribers and the need for more clinical evidence to guide such applications.

Product Types and Modes of Use

The Releaf survey also examined the range of prescribed product types. A striking 90 percent of respondents said they use cannabis flower prescribed for vaporization, while 50 percent use oil formulations. Nearly half were also prescribed vape cartridges, typically containing measured doses of cannabis extract. Each product type offers different therapeutic profiles. Flower-based products provide more immediate symptom relief, whereas oils and cartridges can offer longer, more consistent effects.

Clinical pharmacologists emphasize that the choice between these forms should depend on individual clinical assessment, including symptom type, timing of relief, and patient tolerance. Releaf’s findings suggest British prescribing patterns closely resemble those observed in other early-legalization markets such as Canada and Australia, where inhaled products initially dominate before oils and capsules gain ground.

Demographics and Social Barriers

Nearly 56 percent of Releaf’s respondents were between ages 35 and 54, indicating a midlife concentration among patients. Another 25 percent were over 55, while just under one in five were younger than 35. This pattern reflects a demographic commonly affected by chronic pain and stress-related conditions, yet still professionally active and socially visible—an important factor as perceptions of cannabis use evolve.

Despite the overall improvement in acceptance, stigma remains an obstacle. Ninety-seven percent said they had disclosed their cannabis use to others, signaling growing openness. However, one-fifth still reported experiencing stigma tied to their patient status. The source of this stigmatization varied, with some citing negative attitudes from healthcare professionals, employers, or relatives. Social psychologists studying the data argue that persistent stigma continues to undermine adherence and transparency, deterring open communication between patients and clinicians.

A Complex Legal and Policy Landscape

While the findings portray positive patient outcomes, they also reveal an industry constrained by red tape and inconsistent guidance. The All-Party Parliamentary Group (APPG) for Medical Cannabis under Prescription released its own report around the same time, arguing that the UK’s regulatory environment is still too restrictive. The group contends that limited specialist prescribers, inconsistent import rules, and fragmented prescribing frameworks are slowing progress and keeping costs high.

Health policy analysts routinely describe Britain’s medical cannabis system as “legally available but practically limited.” Unlike in jurisdictions such as Germany or Canada, where public insurance can cover cannabis-based medicines, UK patients typically pay out-of-pocket for private treatment—costs that can exceed several hundred pounds per month. This financial barrier restricts access and disproportionately affects lower-income patients.

The Role of Private Clinics in Expanding Access

Releaf UK represents a new generation of online-first clinics that emerged to meet rising patient demand. These clinics operate under legal prescription frameworks, employing specialist physicians authorized by the General Medical Council to prescribe cannabis-based medicines. The digital model allows patients to undergo assessments remotely and receive medication delivered through registered pharmacies.

Critics question whether this model incentivizes prescriptions without sufficient oversight, given the commercial interests involved. Releaf’s leadership has maintained that its clinical protocols meet all Care Quality Commission (CQC) standards, emphasizing that each prescription follows a medical review process similar to any specialist consultation. Independent health service evaluators note that while private clinics have expanded patient access, broader integration into NHS systems and more public education remain essential to ensure long-term legitimacy.

Public Health Considerations and Driving Habits

Given the psychoactive properties of cannabis, one aspect of the survey focused on driving behavior—a recurring issue in medical cannabis practice. Approximately 51.4 percent of respondents said they avoided driving if they had taken their medication earlier that same day, while around 40 percent said they would drive only if they felt unimpaired. These self-reported figures highlight the need for clearer legal definitions of impairment thresholds and patient guidance.

Traffic safety experts call for a standardized framework similar to those in Canada and Australia, where medical cannabis users can maintain driving privileges under clear medical documentation and blood-THC limits. In the UK, however, impaired driving laws remain strict, and patients risk prosecution if THC levels exceed prescribed thresholds even when medication is taken responsibly. Advocacy groups are pressing the Home Office to revisit these regulations, arguing that current standards do not adequately differentiate medical from non-medical use.

Beyond Symptoms: The Social Ripple of Normalization

Releaf’s data also captures a subtle but meaningful shift in public perception. The willingness of nearly all participants to disclose their treatment suggests cannabis is gradually emerging from the social margins into the mainstream of legitimate medicine. Patient advocacy organizations say this transition mirrors broader cultural shifts in how the public views chronic pain, mental health, and holistic therapy models.

A senior sociologist specializing in drug policy at a British university commented that “the steady normalization of medical cannabis use does not merely reflect changing laws but a changing moral calculus. People increasingly see cannabis as part of therapeutic self-management rather than illicit behavior.” This evolution, experts say, matters not only for patients but also for shaping public policy around safe, evidence-based access.

Challenges Ahead: Evidence, Costs, and Regulatory Cohesion

Despite strong patient satisfaction figures, the field continues to face skepticism from parts of the medical establishment. Many clinicians remain hesitant to prescribe cannabis without more robust peer-reviewed evidence. Clinical research in the UK has expanded slowly since legalization, largely because of bureaucratic constraints on controlled substances research. However, academic hospitals including University College London and Imperial College are now conducting outcome-based studies on chronic pain and post-traumatic stress disorder, which could inform future prescribing standards.

Economically, high out-of-pocket costs pose a long-term sustainability issue. Experts estimate that fewer than 5 percent of potentially eligible patients in the UK currently receive legal cannabis prescriptions. Expanding NHS coverage would require a change in national guideline frameworks issued by the National Institute for Health and Care Excellence (NICE). Previous reviews found insufficient large-scale clinical evidence to recommend routine NHS funding, a position campaigners are urging be revisited as patient data accumulates.

Seven Years On: Measuring Progress Against Promise

As of November 2025, medical cannabis has been legal in the UK for seven years. Yet patients, clinicians, and policymakers all acknowledge that the sector remains in transition. The Releaf survey demonstrates that when prescriptions are accessible, outcomes can be genuinely positive, and side-effect profiles appear manageable. Still, the journey toward normalization and robust clinical integration remains incomplete.

Advocates argue that the next phase for UK medical cannabis must prioritize data transparency, clinician education, and equitable pricing models. Without these, patient progress risks being confined to those who can afford private care. Several parliamentary working groups are now reviewing proposals to streamline import and prescription systems, which could improve consistency and reduce costs.

On a broader scale, the survey illustrates that patient experience is a powerful yet underutilized form of evidence. Real-world data, when collected rigorously, offers policymakers a ground-level view of what is and isn’t working. It also signals a growing public willingness to treat medical cannabis as part of a legitimate health toolkit rather than a fringe experiment.

The Road Ahead for UK Cannabis Medicine

While scientific consensus around optimal dosing, formulations, and long-term outcomes is still forming, the direction appears clear. Patients are using legal cannabis therapeutically, many with measurable success. What remains crucial is ensuring that oversight, research, and safety infrastructure evolve just as rapidly.

The Releaf results carry weight not because they claim to prove cannabis is a cure-all but because they record an emergent clinical reality. Patients are already using these medicines, often with complex conditions and under medical supervision, to reclaim a measure of quality of life. Policymakers and researchers now face the task of bridging the gap between anecdotal patient success and evidence-based medical practice.

As the seventh anniversary of medical cannabis legalization passes, the UK faces a defining choice: whether to treat patient outcomes like those in Releaf’s survey as peripheral data or as a mandate for progress. The evidence suggests that while challenges remain, acceptance, access, and patient legitimacy are steadily gaining ground, signaling a maturing market with the potential to reshape chronic care in Britain if supported by clearer policy and continued science-driven oversight.